Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus (Q45723016)

15 December 2017

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus (English)

1 reference

15 December 2017

Dan J Smith

1

1 reference

15 December 2017

Simona Bot

series ordinal

2

1 reference

15 December 2017

Luis Dellamary

series ordinal

3

1 reference

15 December 2017

Adrian Bot

series ordinal

4

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

15 December 2017

1 reference

15 December 2017

21

1 reference

15 December 2017

2805-2812

1 reference

15 December 2017

21-22

1 reference

Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa

15 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Hollow porous particles in metered dose inhalers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

Strain specificity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900224-X

7 January 2021

10.1016/S0264-410X(03)00224-X

Identifiers

DOI

1 reference

15 December 2017

1 reference